Last10K.com

Teva Pharmaceutical Industries Ltd (TEVA) SEC Filing 8-K Material Event for the period ending Thursday, November 7, 2019

Teva Pharmaceutical Industries Ltd

HISTORY TOOLS
CIK: 1724570 Ticker: TEVA

View differences made from one to another to evaluate Teva Pharmaceutical Industries Ltd's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Teva Pharmaceutical Industries Ltd.

Continue

Assess how Teva Pharmaceutical Industries Ltd's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Teva Pharmaceutical Industries Ltd's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Document And Entity Information

Material Contracts, Statements, Certifications & more

Teva Pharmaceutical Industries Ltd provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Additional Exhibits
Ticker: TEVA
CIK: 818686
Form Type: 8-K Corporate News
Accession Number: 0001157523-19-002224
Submitted to the SEC: Thu Nov 07 2019 7:05:58 AM EST
Accepted by the SEC: Thu Nov 07 2019
Period: Thursday, November 7, 2019
Industry: Pharmaceutical Preparations
Events:
  1. Event for Officers
  2. Financial Exhibit

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/teva/0001157523-19-002224.htm